Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8109175 | 1.00 | DCPS (0.53) | DCPSMAPTCYP2D6DPP4CHRM4 | |
| SCHEMBL24093239 | 0.82 | DRD2 (0.60) | DCPSCYP2D6PDE2ADRD2SLC6A3 | |
| SCHEMBL6941984 | 0.81 | CHRM3 (0.66) | MAPTCYP2D6CHRM4GNAI3CHRM2 | |
| SCHEMBL8110360 | 0.81 | CHRM3 (0.66) | MAPTCYP2D6CHRM4GNAI3CHRM2 | |
| SCHEMBL19974180 | 0.79 | SLC6A4 (0.59) | DCPSCYP2D6GNAI3CHRM2DRD2 | |
| SCHEMBL2095321 | 0.79 | SLC6A3 (0.49) | DCPSCYP2D6HCRTR1HCRTR2PDE2A | |
| SCHEMBL27891441 | 0.79 | CYP2A13 (0.58) | DCPSCYP2D6DRD2SLC6A3EPHX2 | |
| Hydrochloric Acid SCHEMBL11539098 | 0.79 | CHRM3 (0.64) | MAPTCYP2D6CHRM4GNAI3CHRM2 | |
| SCHEMBL6944191 | 0.78 | KDM4E (0.63) | CYP2D6CHRM1C5AR1CYP2C9 | |
| SCHEMBL15821737 | 0.76 | FNTA (0.48) | CHRM4EPHX2CYP2C9CYP2J2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1143858-C | 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof | ������ҩ������˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | DCPS 339/4885MAPT 2525/4885CYP2D6 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.